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Abstract
 
Mycobacterium tuberculosis
 
 represents a world-wide health risk and immunosuppression is a partic-
ular problem in 
 
M. tuberculosis
 
 infections. Although macrophages are primarily infected, dendritic
cells (DCs) are important in inducing cellular immune responses against 
 
M. tuberculosis
 
. We hy-
pothesized that DCs represent a target for 
 
M. tuberculosis
 
 and that the observed immuno-suppres-
sion results from modulation of DC functions. We demonstrate that the DC-specific C-type lec-
tin DC-SIGN is an important receptor on DCs that captures and internalizes intact 
 
Mycobacterium
 
bovis
 
 bacillus Calmette-Guérin (BCG) through the mycobacterial cell wall component ManLAM.
Antibodies against DC-SIGN block 
 
M. bovis
 
 BCG infection of DCs. ManLAM is also secreted
by 
 
M. tuberculosis
 
–infected macrophages and has been implicated as a virulence factor. Strikingly,
ManLAM binding to DC-SIGN prevents mycobacteria- or LPS-induced DC maturation. Both
 
mycobacteria and LPS induce DC maturation through Toll-like receptor (TLR) signaling,
suggesting that DC-SIGN, upon binding of ManLAM, interferes with TLR-mediated signals.
 
Blocking antibodies against DC-SIGN reverse the ManLAM-mediated immunosuppressive
effects. Our results suggest that 
 
M. tuberculosis
 
 targets DC-SIGN both to infect DCs and to
down-regulate DC-mediated immune responses. Moreover, we demonstrate that DC-SIGN has
a broader pathogen recognition profile than previously shown, suggesting that DC-SIGN may
represent a molecular target for clinical intervention in infections other than HIV-1.
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Introduction
 
Tuberculosis has been a major world-wide cause of death
for centuries. One third of the world’s population is in-
 
fected with 
 
Mycobacterium tuberculosis
 
, which causes 2 million
deaths per year. Macrophages are the primary targets for 
 
M.
tuberculosis
 
, and the mycobacteria survive within so called
phagosomes of the infected macrophages. Initially, innate
immune responses against mycobacteria predominate and
are directed by activated macrophages (for a review, see ref-
erence 1). However, subsequent recruitment of cellular re-
sponses that restrict mycobacterial infections, are mediated
 
by dendritic cells (DCs)
 
*
 
 (2). Immature DCs are seeded
throughout peripheral tissues to act as sentinels against in-
vading pathogens. Upon pathogen capture, DCs are acti-
vated, process pathogens into antigenic peptides for presen-
tation in association with either MHC II or nonclassical
MHC-like molecules such as CD1, and migrate to the sec-
ondary lymphoid organs where they activate naive T cells to
initiate adaptive immune responses (3). Indeed, immature
DCs internalize 
 
M. tuberculosis
 
–derived lipoarabinomannans
and present these structures via the CD1b-presentation
pathway to lipoarabinomannan-specific T cells (4).
After the initial reactive phase, 
 
M. tuberculosis
 
 infections
are restricted by cellular immune responses and enter a
chronic latent phase in the host. However, latent infections
have the potential to reactivate and cause clinical tubercu-
losis (5, 6). The ability of 
 
M. tuberculosis
 
 to exist as a latent
infection of the host suggests that mycobacteria are able to
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suppress cellular immune responses. Although DCs are not
the primary targets for infection by mycobacteria, the spe-
cific function of DCs in the cellular immune response
seems to be modulated by mycobacteria (7). Thus, knowl-
edge about the interaction of DCs with mycobacteria and
mycobacterial components is essential to fully understand
and combat 
 
M. tuberculosis
 
 infections.
The interaction of mycobacteria with macrophages has
been extensively investigated and the mannose receptor
(MR), CD11b, and CD11c have been demonstrated to act
as receptors on macrophages for mycobacteria (8, 9). Al-
though these receptors also have been implicated in the in-
teraction of mycobacteria with DCs (4, 7), little is known
about the actual cell-surface receptors on DCs that are in-
volved in DC–mycobacteria interactions. We have recently
identified the DC-specific C-type lectin DC-SIGN that
plays a key role in the dissemination of HIV-1 by DCs
through HIV-1 gp120 binding (10). DC-SIGN has a high
affinity for mannose-containing carbohydrates (11, 12) and
we hypothesized that, based on its carbohydrate recogni-
tion profile, DC-SIGN might function as a receptor for
pathogens other than HIV-1.
We have investigated the interaction of DC-SIGN with
mycobacteria and demonstrate that DC-SIGN is an impor-
tant receptor on DCs for viable mycobacteria, such as 
 
M.
tuberculosis
 
 and 
 
M. bovis 
 
bacillus Calmette-Guérin (BCG),
and ManLAM, despite the presence of the other reported
mycobacterial receptors. We demonstrate that mycobacte-
ria specifically target DC-SIGN through ManLAM to im-
pair DC maturation and to induce production of the anti-
inflammatory cytokine IL-10. These conditions promote
immunosuppression and may contribute to the survival of
 
M. tuberculosis
 
. These results imply that clinical strategies
targeting DC-SIGN function could succeed in combating
 
M. tuberculosis
 
 infections by shifting the precarious balance
between immune activation and suppression to favor the
elimination of mycobacteria.
 
Materials and Methods
 
Antibodies.
 
The following antibodies were used: anti-MR
(Clone 19; BD Biosciences), CD11b (bear-1; reference 13),
CD11c (SHCL3; reference 14), anti-DC-SIGN (AZN-D1,
AZN-D2 [12], CSRD [15]), LAMP-1 (H4A3; BD Biosiences),
and the PE-conjugated antibodies CD80, CD86, HLA-DR (BD
Biosciences), and CD83 (Beckman Coulter).
 
Cells.
 
Immature DCs were cultured from monocytes in the
presence of IL-4 and GM-CSF (500 and 800 U/ml, respectively;
Schering-Plough; reference 16). K562 transfectants expressing
wild-type DC-SIGN were generated by transfection of K562
cells with 10 
 
 
 
g pRc/CMV-DC-SIGN plasmid by electropora-
tion as described previously (10).
 
Mycobacteria. M. smegmatis
 
, 
 
M. bovis
 
 BCG (Pasteur), 
 
M. tuber-
culosis
 
 strains H37Ra and H37Rv, and 
 
M. paratuberculosis
 
 were
gifts from A. Kolk (Royal Tropical Institute, Amsterdam, Neth-
erlands). 
 
M. bovis
 
 BCG was cultured in vitro using Middelbrook
7H9 broth supplemented with 0.05% Tween 80 and albumin-
dextrose-catalase. The glycolipids ManLAM and AraLAM were
obtained from J. Belisle, Colorado State University, Fort Collins,
 
CO, and the National Institutes of Health, Bethesda, MD (con-
tract NO1 AI-75320). DCs were infected with mycobacteria by
coculturing them at an appropriate multiplicity of infection
(MOI) as indicated in the figure legends.
Capture and internalization of mycobacteria by cells was eval-
uated using FITC-conjugated 
 
M. bovis
 
 BCG. Bacteria (10
 
9
 
/ml)
were labeled by incubation of 0.5 mg FITC per ml in phosphate-
buffered saline (pH 7.4) at room temperature for 1 h. The FITC-
pulsed bacteria were washed three times to remove unbound
FITC. Capture was determined by measuring the percentage of
cells that bound FITC-conjugated bacteria using flow cytometry
(FACSCalibur™; Becton Dickinson). Phagocytosis was deter-
mined using a fluorescence-quenching technique as reported pre-
viously (17). In brief, quenching of noninternalized membrane-
bound FITC-conjugated 
 
M. bovis
 
 BCG was achieved by treating
the cells with 0.05% trypan blue for 5 min.
 
Fluorescent Bead Adhesion Assay.
 
Carboxylate-modified Trans-
FluorSpheres (488/645 nm, 1.0 
 
 
 
m; Molecular Probes) were
coated with the glycolipid forms of lipoarabinomannan (LAM).
Streptavidin-coated beads (18) were incubated with biotinylated
F(ab
 
 
 
)
 
2
 
 fragment goat anti–mouse IgG (6 
 
 
 
g/ml; Jackson Immuno-
Research Laboratories) followed by an overnight incubation with
mouse-anti-LAM antibody (F30.5) at 4
 
 
 
C. The beads were
washed and incubated with 250 ng/ml purified glycolipid LAM
overnight at 4
 
 
 
C. The fluorescent beads adhesion assay was per-
formed as described by Geijtenbeek et al. (18).
 
Soluble DC-SIGN-Fc Adhesion Assay.
 
DC-SIGN-Fc consists
of the extracellular portion of DC-SIGN (amino acid residues
64–404) fused at the COOH terminus to a human IgG1-Fc frag-
ment (19). The soluble DC-SIGN adhesion assay was performed
as follows. Soluble ligands were coated onto ELISA plates (1 
 
 
 
g/
well for purified proteins and 5 
 
 
 
g/well for lysates) for 18 h
at room temperature, followed by blocking with 1% BSA for 2 h
at 37
 
 
 
C. Soluble DC-SIGN-Fc supernatant was added for 30 min at
37
 
 
 
C. Unbound DC-SIGN-Fc was washed away and binding
was determined by anti-IgG1 ELISA. Specificity was determined
in the presence of either 50 
 
 
 
g/ml blocking antibodies, 50 
 
 
 
g/
ml mannan or 5 mM EGTA.
 
DC Activation.
 
Immature DCs (2 
 
 
 
 10
 
6
 
 cells/ml) were cul-
tured for 24 h in the presence of IL-4 (500 U/ml; Schering-
Plough), GM-CSF (800 U/m; Schering-Plough), and either LPS
(10 ng/ml) or LAM glycolipids (15 
 
 
 
g/ml). The effect of LAM
on LPS-induced activation was determined by preincubating im-
mature DCs (300,000 cells) with AZN-D2 (40 
 
 
 
g/ml) for 30
min, and subsequently with LPS in the presence of LAM (15 
 
 
 
g/
ml) for 18 h. LAM glycolipids were obtained from J. Belisle
(Colorado State University and the National Institutes of Health
[contract NO1 AI-75320]) and contained 
 
 
 
5 ng/mg endotoxin.
Activation was determined by cell-surface expression of MHC
class II (HLA-DR) and the costimulatory molecules CD80,
CD83, and CD86 using PE-conjugated antibodies.
 
Cytokine Production.
 
For the detection of cytokines, culture
supernatants were harvested at day 1 and frozen at 
 
 
 
80
 
 
 
C until
analysis. The supernatants were analyzed for the presence of IL-
10 and IL-12p40 by ELISA (Biosource International).
 
Results
 
DC-SIGN Interacts with M. tuberculosis through ManLAM
Glycolipids.
 
The interaction of DC-SIGN with different
mycobacteria strains was investigated using the DC-SIGN-
Fc binding assay (19). DC-SIGN-Fc specifically interactedT
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with the lysates from both virulent and avirulent 
 
M. tuber-
culosis
 
 strains, as the interaction was inhibited with blocking
antibodies against DC-SIGN (Fig. 1 a). Moreover, DC-
SIGN also interacted with the lysates from other mycobac-
teria strains, such as 
 
M. bovis
 
 BCG and 
 
M. paratuberculosis
 
(Fig. 1 a). Next, we investigated whether DC-SIGN-Fc
also interacts with viable mycobacteria. Therefore, viable
 
M. tuberculosis
 
 H37Ra and 
 
M. bovis
 
 BCG were coated and
the interaction of DC-SIGN with these pathogens was an-
alyzed using the DC-SIGN-Fc binding assay (19). 
 
M. bovis
 
BCG is a tuberculosis vaccine strain that is mildly virulent
but nonpathogenic, yet retains some immunological prop-
erties of tuberculosis (20). DC-SIGN-Fc interacted specifi-
cally with both 
 
M. tuberculosis
 
 H37Ra and 
 
M. bovis
 
 BCG, as
the interaction was inhibited with blocking DC-SIGN–
specific antibodies (Fig. 1 b). Moreover, an irrelevant Fc
chimera, intercellular adhesion molecule (ICAM)-3-Fc, did
not interact with the mycobacteria (Fig. 1 b). The interac-
tion is mediated by the C-type lectin domain of DC-
SIGN, as binding to both 
 
M. tuberculosis
 
 and 
 
M. bovis
 
 BCG
was inhibited by either the Ca
 
2
 
 
 
-chelator EGTA, mannan,
or the DC-SIGN–specific antibody AZN-D1 that recog-
nizes the lectin domain (19; Fig. 1 b). We next investigated
the binding of DC-SIGN to purified mycobacterial cell
wall lipoarabinomannan (LAM), as DC-SIGN has a high
affinity for mannose-containing carbohydrates (11, 12) and
LAM comprises a mannose-rich polysaccharide core, con-
taining highly branched arabinofuranosyl side chains, and a
GPI anchor (21). LAM isolated from 
 
M. tuberculosis
 
 con-
tains mannose residues consisting exclusively of mono-, di-,
and trimers of 
 
 
 
-
 
d
 
-mannoses directly linked to the ara-
binofuranosyl-termini and is called ManLAM, whereas
LAM isolated from the fast growing 
 
M. smegmatis
 
 is not
mannose-capped and is called AraLAM (21). Strikingly,
purified ManLAM was efficiently bound by DC-SIGN, in
contrast to AraLAM (Fig. 1 c), demonstrating that DC-
SIGN specifically interacts with the mono-, di-, and tri-
mers of 
 
 
 
-
 
d
 
-mannoses of ManLAM. Even at high concen-
trations, DC-SIGN did not bind AraLAM, demonstrating a
high specificity for ManLAM and its mannose-cap (Fig. 1
d). The interaction of DC-SIGN with ManLAM is spe-
cific, as the binding was inhibited by antibodies against
DC-SIGN, whereas an irrelevant Fc chimera did not inter-
act with ManLAM (Fig. 1 c). These data suggest that DC-
SIGN interacts with various mycobacteria strains that con-
tain ManLAM, whereas it may not bind mycobacteria
strains that contain LAM without the mannose-cap, such as
 
M. smegmatis
 
.
 
Both Mycobacteria and ManLAM Interact with the Primary
Binding Site of DC-SIGN.
 
We used K562 transfectants
stably expressing DC-SIGN to investigate the binding of
cell-surface–expressed DC-SIGN to 
 
M. bovis
 
 BCG, 
 
M.
smegmatis
 
, and the mycobacterial component ManLAM.
These cells do not express the previously reported myco-
bacterial receptors MR, CD11b, and CD11c (8, 9; Fig. 2
a). K562 transfectants express high levels of DC-SIGN
(Fig. 2 a) and bind strongly to both viable 
 
M. bovis
 
 BCG
and ManLAM, in contrast to mock transfected K562 cells
(Fig. 2 b). The interaction is blocked by DC-SIGN–spe-
cific antibodies (Fig. 2 b). DC-SIGN did not bind to viable
 
M. smegmatis
 
, which contains uncapped AraLAM (Fig. 2 b).
This supports the hypothesis that DC-SIGN binds Man-
LAM on 
 
M. bovis
 
 BCG. The interaction of DC-SIGN
with both 
 
M. bovis
 
 BCG and ManLAM is similar to that of
the other DC-SIGN ligands ICAM-3 and HIV-1 (Fig. 2
b). DC-SIGN expressed by K562 transfectants did not in-
Figure 1. DC-SIGN specifically binds ManLAM, a
cell wall component of M. tuberculosis. (a) DC-SIGN
interacts with several mycobacteria strains. DC-SIGN-
Fc binding to mycobacteria (lysates; 5  g) was deter-
mined by a Fc-specific ELISA. Specificity was deter-
mined by measuring binding in the presence of
blocking DC-SIGN–specific antibodies (AZN-D1).
Standard deviation  0.02 OD450. One representative
experiment out of three is shown. (b) DC-SIGN inter-
acts with viable mycobacteria strains. DC-SIGN-Fc
binding to viable mycobacteria (5   105 bacteria) was
determined by a Fc-specific ELISA. Specificity was de-
termined by measuring binding in the presence of
blocking DC-SIGN–specific antibodies (AZN-D1 or
AZN-D3) and mannan. EGTA was used to determine
the calcium dependency of the DC-SIGN-Fc–medi-
ated binding. ICAM-3-Fc binding to mycobacteria
was also measured to exclude nonspecific binding by
the Fc domain. Standard deviation  0.02 OD450.
One representative experiment out of three is shown.
(c) The mannosylated-lipoarabinomannan ManLAM,
in contrast to the nonmannosylated AraLAM, is specif-
ically bound by DC-SIGN. The anti–DC-SIGN anti-
body AZN-D1 was used to determine specificity. The
DC-SIGN-Fc binding assay was performed as de-
scribed for panel a. Standard deviation  0.02 OD450.
One representative experiment out of three is shown. (d) DC-SIGN does not interact with AraLAM. The DC-SIGN-Fc binding assay was performed
as described for panel a. One representative experiment out of three is shown.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
10
 
DC-SIGN Binding to ManLAM Blocks DC Maturation
 
teract with AraLAM (unpublished data). Thus, cellular
DC-SIGN specifically binds to both 
 
M. bovis
 
 BCG and
ManLAM, as was observed with recombinant DC-SIGN-
Fc (Fig. 1 c).
The C-type lectin domain of DC-SIGN contains two
calcium ions (12), and the amino acid residues that are in
close contact with Ca
 
2
 
 
 
 at site 2 (Glu
 
347
 
, Asn349, Glu354, and
Asn365) form the core of the ligand binding site (19, 22).
Changing in DC-SIGN either Glu347 into Gln (E347Q), or
Asn349 and Asn365 into Asp, resulted in complete loss of
binding to viable mycobacteria and ManLAM (Fig. 2 b,
and unpublished data), as was previously shown for both
ICAM-3 and HIV-1 gp120 (Fig. 2 b, and reference 19).
The Ca2  at site 1, the so-called auxiliary site, coordinates
the correct positioning of the primary binding site (19, 22),
and loss of this Ca2  by mutating Asp320, Glu324 (E324A),
Asn350, or Asp355 into Ala residues resulted in complete loss
of both M. bovis BCG and ManLAM binding (Fig. 2 b, and
unpublished data).
Recently, we demonstrated that the binding site of DC-
SIGN for its cellular ligand ICAM-3 is distinct from that of
HIV-1 gp120 (19), as a specific mutation in DC-SIGN
(V351G) abrogated ICAM-3, but not HIV-1 gp120 bind-
ing (Fig. 2 c, and reference 19). Strikingly, the DC-SIGN
V351G mutant also interacts with M. bovis BCG as well as
ManLAM (Fig. 2 c), demonstrating that both HIV-1 and
mycobacteria bind similarly to DC-SIGN at a distinct site
from the cellular ligand ICAM-3.
DC-SIGN Is an Important Receptor for Mycobacteria on
DCs. Immature DCs express, besides high levels of DC-
SIGN, high levels of the receptors MR, CD11b, and
CD11c (Fig. 3 a), which have previously been reported to
mediate binding of mycobacteria by macrophages (8, 9).
We used blocking antibodies against these receptors to
evaluate their contributions to ManLAM binding by DCs.
Immature DCs bind strongly to ManLAM, but not to
AraLAM, and the interaction was inhibited by the DC-
SIGN–specific antibody, but strikingly not by any of the
antibodies against MR, CD11b, or CD11c (Fig. 3 b). Both
EGTA and the C-type lectin-specific inhibitor mannan
block ManLAM binding by DCs to a similar extent as the
DC-SIGN–specific antibodies, demonstrating that DC-
SIGN is an important ManLAM-binding C-type lectin on
immature DCs (Fig. 3 b).
The major contribution of DC-SIGN to the interaction
of immature DCs with ManLAM prompted us to investi-
gate whether DC-SIGN was also important in the interac-
tion of immature DCs to viable mycobacteria. Immature
DCs interacted strongly with M. bovis BCG (Fig. 3 c).
Strikingly, DC-SIGN is an important receptor for M. bovis
BCG, as the antibodies against DC-SIGN strongly inhib-
ited the infection of immature DCs with M. bovis BCG
(Fig. 3 c). Antibodies against MR, CD11b, and CD11c did
not inhibit the infection, whereas the C-type lectin inhibi-
tor mannan blocked the infection to a similar level as the
DC-SIGN antibodies (Fig. 3 c). Moreover, the MR-ligand
mannose-BSA did not inhibit the interaction of DCs with
M. bovis BCG (Fig. 3 c) demonstrating that the C-type lec-
tin domains of MR are not involved in M. bovis BCG in-
fection of DCs. Both the anti-MR antibody and mannose-
BSA are inhibitors of MR function as they block binding
of another MR-ligand, dextran, to DCs (unpublished data).
Figure 2. Cellular DC-SIGN binds strongly to both viable mycobacteria
and the mycobacterial component ManLAM through its primary binding
site. (a) K562-DC-SIGN transfectants express high levels of DC-SIGN but
lack expression of the other reported ManLAM receptors MR, CD11b, and
CD11c. Transfectants were generated as described previously (reference
12). Open histograms represent the isotype controls, and filled histograms
indicate the specific antibody staining. (b) DC-SIGN, expressed by K562
transfectants, binds strongly to intact M. bovis BCG and the mycobacterial
component ManLAM but not to M. smegmatis and AraLAM. The adhesion
of cells to the LAM glycans was determined using the fluorescent bead ad-
hesion assay. Binding to viable mycobacteria was determined by measuring
the binding of K562 transfectants to FITC-conjugated mycobacteria (MOI
20) using flow cytometry. Specificity was determined by measuring binding
in the presence of blocking antibodies against DC-SIGN. Standard devia-
tion for the fluorescent bead adhesion assay and the mycobacteria binding
assay was  5 and  2%, respectively. One representative experiment out of
three is shown. (c) The Val351 amino acid residue is not essential for the in-
teraction of DC-SIGN with M. bovis BCG and ManLAM, similar to HIV-1
gp120, whereas it is essential for ICAM-3 binding. Binding to the V351G
DC-SIGN mutant expressed by K562 cells was measured as described for
panel b. Specificity was determined by measuring binding in the presence of
blocking antibodies against DC-SIGN, mannan or EGTA. Standard devia-
tion  5% (fluorescent bead adhesion assay) and  2% (mycobacteria bind-
ing assay). One representative experiment out of three is shown.T
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These results demonstrate that DC-SIGN is an important
C-type lectin on DCs that functions as a receptor for M.
bovis BCG. Other nonlectin receptors may contribute to
the interaction, as the infection was not completely inhib-
ited by antibodies against DC-SIGN (Fig. 3 c).
Next, we investigated whether DC-SIGN mediates in-
ternalization of M. bovis BCG by using the trypan blue
method to quench surface FITC-conjugated mycobacteria.
Mock transfected K562 cells did not phagocytose M. bovis
BCG, whereas 50% of the K562 transfectant, expressing
DC-SIGN, had internalized M. bovis BCG within 45 min
(Fig. 3 d). Both mannan and antibodies against DC-SIGN
blocked the internalization of M. bovis BCG (Fig. 3 d).
Immature DCs are highly phagocytoic cells and indeed
within 45 min  90% of the DCs that bound viable M. bo-
vis BCG, had also internalized the mycobacteria (Fig. 3 e).
As was observed for the binding of M. bovis BCG by DCs
(Fig. 3c), phagocytosis of M. bovis BCG is partly blocked
by antibodies against DC-SIGN, whereas both anti-MR
antibodies and the MR-ligand mannose-BSA did not in-
hibit the observed phagocytosis (Fig. 3 e). Both anti-MR
antibodies and the MR-ligand mannose–BSA blocked in-
ternalization of dextran by immature DC (unpublished
data). These results demonstrate that DC-SIGN enables the
capture and internalization of M. bovis BCG by immature
DCs through binding of the mycobacterial cell wall com-
ponent ManLAM.
Mycobacteria and ManLAM Are Internalized by DC-SIGN
and Targeted to Lysosomes. Recently, we have demon-
strated that DC-SIGN can function as an antigen receptor
that internalizes antigens and targets them to lysosomal
compartments for presentation on MHC class II (15).
Therefore, the fate of the captured M. bovis BCG by imma-
ture DCs was followed by immunofluorescence analyses.
Immature DCs were infected with FITC-conjugated M.
bovis BCG for 2 h and both DC-SIGN and the lysosomal
marker LAMP-1/CD107a were stained (Fig. 4 a). The ob-
served colocalization of DC-SIGN with FITC-conjugated
M. bovis BCG further supports a role for DC-SIGN in the
capture and internalization of mycobacteria (Fig. 4 a). Phago-
cytosed mycobacteria were targeted to lysosomes, as the in-
ternalized FITC-conjugated mycobacteria colocalized with
LAMP-1 staining (Fig. 4 a). Similarly, ManLAM was also
captured and internalized by DC-SIGN on immature DCs,
as ManLAM staining colocalized with DC-SIGN (Fig. 4 a)
whereas AraLAM was not internalized by DCs (un-
published data). Internalized ManLAM colocalized with
LAMP-1 in immature DC (Fig. 4 a) indicating that inter-
nalized ManLAM is targeted to lysosomes.
Recently, we demonstrated that binding of soluble
ligands or antibodies to DC-SIGN triggers internalization
of the DC-SIGN–ligand complex to late endosomes/lyso-
somes, and results in down-regulation of DC-SIGN from
the surface (15). Therefore, we investigated whether DC-
SIGN was internalized after ManLAM binding by measur-
ing the cell-surface expression of DC-SIGN after Man-
LAM binding using a specific antibody against DC-SIGN
(15). Indeed, binding of ManLAM, but not AraLAM, to
DC-SIGN resulted in down-regulation of DC-SIGN (Fig.
4 b), demonstrating that DC-SIGN on DCs binds Man-
LAM and mediates the internalization of ManLAM to
Figure 3. DC-SIGN is an important receptor for both ManLAM and my-
cobacteria on DCs. (a) Immature DCs express high levels of DC-SIGN and
the other reported LAM receptors MR, CD11b, and CD11c. Open histo-
grams represent isotype control and filled histograms indicate specific anti-
body staining. (b) Immature DCs bind strongly to ManLAM via DC-SIGN.
Binding was determined using the fluorescent bead adhesion assay. Specificity
was determined by measuring binding in the presence of mannan, EGTA or
blocking antibodies against DC-SIGN (AZN-D2), MR (Clone 19), CD11b
(bear-1), or CD11c (SHCL3). Standard deviation  5%. One representative
experiment out of three is shown. (c) DC-SIGN mediates capture of M. bovis
BCG by immature DCs. Binding was determined by flow cytometry using
FITC-conjugated mycobacteria. Specificity was determined by measuring
binding in the presence of antibodies against DC-SIGN (AZN-D1, AZN-
D2, and AZN-D3), MR (Clone 19), CD11b (bear-1), and CD11c
(SHCL3). Binding was also measured in the presence of the C-type lectin in-
hibitors mannan and EGTA, whereas a known MR ligand, mannose-BSA,
was used to determine the contribution of the MR receptor. Standard devia-
tion  2%. One representative experiment out of three is shown. (d) DC-
SIGN mediates capture and internalization of M. bovis BCG by K562 cells.
K562 transfectants were incubated with FITC-conjugated M. bovis BCG
(MOI 20). Cells were washed, and surface FITC was quenched by exposure
to trypan blue. Phagocytosis was determined by comparing the FITC emis-
sion before and after quenching using flow cytometry. Surface bound bacte-
ria are represented by open bars, internalized by closed bars. Standard devia-
tion   4%. One representative experiment out of three is shown. (e)
Immature DCs rapidly phagocytose mycobacteria through DC-SIGN. The
internalization was determined as described for panel b. Surface bound bacte-
ria are represented by open bars, internalized by closed bars. Standard devia-
tion  5%. One representative experiment out of three is shown.T
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LAMP-1  lysosomes. However, other mycobacteria recep-
tors such as MR, CD11b, and CD11c were not down-reg-
ulated (Fig. 4 b). Thus, ManLAM binding to DC-SIGN
triggers internalization of the DC-SIGN/ManLAM com-
plex to lysosomes and may enable antigen processing of
ManLAM by DCs.
ManLAM Modulates Cytokine Production by DCs through
DC-SIGN Binding. ManLAM is present not only a my-
cobacterial cell wall component but is also secreted from
phagosomes after macrophage ingestion of M. tuberculosis
(21, 23, 24). Potentially, mycobacteria within infected
macrophages can influence bystander immune cells and
modulate the immune response through secretion of Man-
LAM. The cytokine IL-10 is a potent immunosuppressive
factor induced in macrophages by some intracellular bacte-
ria to dampen down host immune responses and promote
their survival (25). We investigated the influence of Man-
LAM binding to DC-SIGN in IL-10 production by DCs.
ManLAM alone did not induce IL-10 production by im-
mature DC (Fig. 5 a). Strikingly, ManLAM, but not
AraLAM, strongly induced IL-10 production by DCs,
when they received simultaneously an activation signal,
such as LPS (Fig. 5 a). This IL-10 induction was com-
pletely inhibited by DC-SIGN–specific antibodies to the
level of LPS-activated DCs alone (Fig. 5 a). The findings
that only ManLAM could induce IL-10 production,
which could be blocked by DC-SIGN–specific antibodies
indicates that the IL-10 induction is specific for the
ManLAM/DC-SIGN interaction. Antibodies against DC-
SIGN alone did not induce IL-10 production by LPS-acti-
vated DCs (Fig. 5 a), demonstrating that ligation of DC-
SIGN alone is not sufficient for IL-10 induction. Thus, the
binding of ManLAM to DC-SIGN triggers intracellular
signals that induce IL-10 production by DCs, indicating
that mycobacteria target DC-SIGN to suppress the im-
mune response and promote their survival in the host.
Both immature and LPS-activated DCs, alone or in com-
bination with ManLAM, produced very low amounts of
IL-12p70 ( 5 pg/ml). Infection of immature DCs with
M. bovis BCG induced a strong production of IL-10 that
Figure 4. DC-SIGN mediates internalization of captured mycobacteria
and ManLAM. (a) M. bovis BCG and ManLAM are internalized by DC-
SIGN on immature DCs and targeted to the lysosomes. The fate of cap-
tured mycobacteria was followed by analyzing immature DCs pulsed with
FITC-conjugated M. bovis BCG (MOI 20) for 2 h using immunofluores-
cence microscopy (magnification 200 ). ManLAM was followed by in-
cubating DCs with ManLAM (10  g/ml) for 1 h. DC-SIGN, ManLAM,
and CD207a/LAMP-1 were stained with AZN-D1, F30.5, and H4A3,
respectively. One representative experiment out of three is shown. (b)
ManLAM induces down-regulation of DC-SIGN, but not of MR, CD11b,
and CD11c. Immature DCs were incubated with 15  g/ml of ManLAM or
AraLAM for 18 h, and then DC-SIGN expression was determined by flow
cytometry. One representative experiment out of three is shown.
Figure 5. Mycobacteria induce IL-10 production by DCs through
ManLAM and direct infection. (a) ManLAM induces IL-10 production of
LPS-matured DCs. Immature DCs were incubated with 15  g/ml of ei-
ther ManLAM or AraLAM in the presence of LPS (10 ng/ml). The spec-
ificity was determined in the presence of blocking antibodies against DC-
SIGN (AZN-D2; 20  g/ml). Supernatants were harvested after 18 h and
the IL-10 production was measured by ELISA. Values are the means  
standard deviations of triplicate determinations. One representative ex-
periment out of three is shown. (b) M. bovis BCG infection of immature
DCs induces IL-10 production. Immature DCs were infected with M. bo-
vis BCG (MOI 4), and the experiment was performed as described for
panel a. Values are the means   standard deviations of triplicate determi-
nations. One representative experiment out of three is shown.T
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was not inhibited by antibodies against DC-SIGN (Fig. 5
b). No differences were observed in the presence of Man-
LAM (Fig. 5 b). These results suggest that mycobacteria
induce IL-10 production by direct infection as well as by
secreting ManLAM.
ManLAM Inhibits DC Activation through DC-SIGN.
Immature DCs are highly efficient in antigen capture and
processing, whereas mature DCs are specialized in the na-
ive T cell activation necessary for cellular immune re-
sponses (3). Immature DCs mature in response to specific
‘danger’ signals such as bacterial components (LPS) or in-
flammatory cytokines (TNF , PGE2). We investigated the
effect of ManLAM on the maturation of DCs. Neither
ManLAM nor AraLAM induced DC maturation, as both
ManLAM and AraLAM, in contrast to LPS that triggers
Toll-like receptor (TLR)4, did not up-regulate expression
of the activation markers CD80, CD83, CD86, or HLA-
DR (Fig. 6 a).
Acute mycobacterial infections represent sites of inflam-
mation that attract and induce DC maturation through the
presence of maturation components. Therefore, we inves-
tigated the effect of ManLAM and AraLAM in combina-
tion with the stimulatory bacterial LPS. TLR4 interaction
with LPS generates intracellular signaling, most notably via
the transcription factor nuclear factor (NF)- B, that results
in DC activation/maturation. Indeed, DCs efficiently ma-
ture in the presence of LPS alone (Fig. 6 b). Strikingly, this
LPS-induced activation is inhibited in the presence of
ManLAM, as the expression levels of the activation markers
CD80, CD83, and CD86 were considerably lower than
those of LPS-activated DCs (Fig. 6 b). The observed inhi-
bition of DC activation/maturation is specific for Man-
LAM, as AraLAM did not inhibit DC activation (Fig. 6 b).
This is further supported by the ability of antibodies against
DC-SIGN, that inhibit ManLAM binding (Fig. 3 b), to
completely restore LPS-induced maturation in the presence
of ManLAM (Fig. 6 b). These results indicate that Man-
LAM binding to DC-SIGN generates intracellular signals
that interfere with the TLR4-mediated activation of DCs.
Moreover, this process is specific for the ManLAM-DC-
SIGN interaction and DC-SIGN ligation alone is not suffi-
cient, as antibodies against DC-SIGN did not block LPS-
induced DC activation/maturation (Fig. 6 b).
Both M. tuberculosis and M. bovis BCG are able to induce
DC maturation through their cell-wall components via
TLR2- and TLR4-mediated signaling (26–29). Indeed, M.
bovis BCG infection of immature DCs results in DC matu-
ration, as demonstrated by the increased expression of
MHC class II and the costimulatory molecules CD80,
CD83, and CD86 after M. bovis BCG infection (Fig. 7 a).
Next, we investigated whether ManLAM binding to DC-
SIGN prevented M. bovis BCG-induced DC maturation, as
immature DCs attracted to sites of mycobacterial infection
will encounter both secreted ManLAM and intact myco-
bacteria. Strikingly, the M. bovis BCG-induced DC matu-
ration is strongly inhibited by ManLAM (Fig. 7 b). The ex-
pression of MHC class II, CD80, CD83, and CD86 on M.
bovis BCG-infected DCs in the presence of ManLAM was
considerably lower than on M. bovis BCG-infected DCs
(Fig. 7 b). Moreover, the maturation was mostly restored
when DCs were preincubated with the blocking DC-
SIGN–specific antibody (Fig. 7 b), demonstrating that the
ManLAM interaction with DC-SIGN prevents DC matu-
ration by M. bovis BCG. Moreover, AraLAM did not block
the DC maturation by M. bovis BCG (Fig. 6 c), as the co-
stimulatory molecules, CD80, CD83, and CD86, are ex-
pressed at similar levels on both infected DCs and
AraLAM-treated infected DCs. This indicates that the DC-
SIGN–ManLAM interaction blocks the maturation of DCs
induced by LPS as well as M. bovis BCG.
Figure 6. ManLAM inhibits LPS-induced DC activation through DC-
SIGN binding. (a) ManLAM does not induce activation of immature
DCs. Immature DCs were incubated with ManLAM, AraLAM, or LPS
for 18 h, and activation was determined by measuring the expression of
CD80, CD86, CD83, and HLA-DR. Dotted lines represent isotype con-
trols, the thin lines indicate expression levels of immature DCs, and the
thick line represents immature DCs that have been treated with either
LPS (10 ng/ml), ManLAM (15  g/ml), or AraLAM (15  g/ml). One
representative experiment out of three is shown. (b) LPS-induced activa-
tion of DCs is blocked by ManLAM. Immature DCs were cocultured
with LPS alone, or together with either ManLAM or AraLAM for 18 h.
Dotted lines represent isotype controls. Thick lines, and the mean fluores-
cence values in the histograms, represent the expression levels after treat-
ment with LPS alone, or in combination with either ManLAM or
AraLAM. Thin lines indicate the presence of antibodies against DC-
SIGN throughout the incubation. One representative experiment out of
three is shown.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
14 DC-SIGN Binding to ManLAM Blocks DC Maturation
Discussion
DCs are essential for the containment of M. tuberculosis
infections by inducing cellular immune responses against
mycobacteria (30). However, M. tuberculosis infections re-
main latent throughout the host lifetime, demonstrating
that mycobacteria have developed evasive mechanisms to
suppress immune responses and to survive within the host.
The unique function of DCs in eliciting and directing cel-
lular immune responses may be modulated by mycobacte-
ria. We demonstrate here that the DC-specific C-type lec-
tin DC-SIGN is an important receptor on DCs for
mycobacteria that express ManLAM, and that mycobacte-
ria target DC-SIGN on DCs through secreted ManLAM to
block maturation of mycobacteria-infected DCs and to in-
duce the immunosuppressive cytokine IL-10.
Soluble as well as cellular DC-SIGN bind strongly to vi-
able mycobacteria such as M. tuberculosis and M. bovis BCG
(Fig. 1 and 2), but not to M. smegmatis (Fig. 2). A major
cell wall component of these mycobacteria strains is Man-
LAM, a mannose-containing phosphorylated glycolipid
implicated as a virulence factor (21). The LAM from
pathogenic M. tuberculosis strains is between 40–70% man-
nose-capped (21). Strikingly, DC-SIGN binds strongly to
ManLAM, but not to uncapped AraLAM. ManLAM, in
contrast to AraLAM, contains a mannose-cap consisting
exclusively of mono-, di-, and trimers of  -d-mannoses di-
rectly linked to the arabinofuranosyl-termini (21). Thus,
DC-SIGN binds specifically to the exterior  -d-mannose
residues of ManLAM, but not to the mannose-containing
core of ManLAM, which is shared with AraLAM. Accessi-
bility and the spacing of the mannose-containing termini
on ManLAM may contribute to the strong interaction.
Both viable mycobacteria, containing ManLAM, and Man-
LAM alone bind specifically to the primary binding site of
DC-SIGN, similarly to the other DC-SIGN ligands
ICAM-3 and HIV-1 gp120 (Fig. 2). ICAM-3 and gp120
make distinct additional contacts with DC-SIGN, and
Val351 at the edge of the binding pocket denotes the differ-
ence between these ligands. The DC-SIGN V351G mu-
tant does not bind ICAM-3, whereas HIV-1 gp120 is still
bound by this mutant (Fig. 2 c, and reference 19). Both M.
bovis BCG and ManLAM are bound by the DC-SIGN
V351G mutant (Fig. 2), indicating that they have the
same binding site. The cellular ligand ICAM-3 contains
N-linked glycosylations consisting of high mannose-type
oligosaccharides that are essential for DC-SIGN binding,
whereas the binding of HIV-1 gp120 is not exclusively
mediated by high mannose-polycarbohydrates (19). These
data indicate that the DC-SIGN V351G mutant is unable
to bind complex high-mannose structures but remains able
to bind linear mannose residues such as those present in
ManLAM. Thus, the pathogen structures ManLAM and
HIV-1 gp120 occupy a similar binding pocket in DC-
Figure 7. M. bovis BCG induces maturation and
ManLAM inhibits the induced DC activation through
DC-SIGN binding. (a) M. bovis BCG induces matura-
tion of immature DCs. Immature DCs were incubated
with LPS or viable M. bovis BCG (MOI 4, 20, and
100) for 18 h, and activation was determined by mea-
suring the expression of CD80, CD86, CD83, and
HLA-DR. The mean fluorescence intensity (MFI) of
the difference between specific antibody and isotype
control is depicted. One representative experiment out
of three is shown. (b) M. bovis BCG-induced activation
of DCs is blocked by ManLAM. Immature DCs were
infected with M. bovis BCG (MOI 4). Cells were pre-
incubated with 15  g/ml of either ManLAM or
AraLAM and the expression of the markers was mea-
sured after 18 h as described for panel a. Specificity was
determined by preincubating cells with blocking anti-
bodies against DC-SIGN (AZN-D2; 20  g/ml). One
representative experiment out of three is shown.T
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SIGN, that is distinct from that of the cellular ligand
ICAM-3. These observations suggest that DC-SIGN may
distinguish between different types of ligand and may tailor
its responses specifically. These results further support the
hypothesis that DC-SIGN interacts with viable mycobacte-
ria through ManLAM. Indeed, cellular DC-SIGN did not
interact with viable M. smegmatis, demonstrating that DC-
SIGN does not interact with mycobacteria that do not
contain ManLAM.
DC-SIGN is an important receptor on DCs for both M.
bovis BCG and ManLAM (Fig. 3), even though DCs also
express the receptors MR, CD11b, and CD11c that have
previously been implicated in the interactions of myco-
bacteria with both macrophages and DCs (8, 9, 31). DC-
SIGN–specific antibodies, in contrast to MR-specific anti-
bodies, block the interaction of DCs with both M. bovis
BCG and ManLAM (Fig. 3). Involvement of MR in
ManLAM binding by DCs has previously been inferred by
inhibition studies using mannan (4, 7), as MR has a high
affinity for this polycarbohydrate. However, mannan also
inhibits the functions of other C-type lectins on DCs,
such as DC-SIGN (for a review, see reference 32), dem-
onstrating that specific blocking antibodies against particu-
lar receptors are necessary to accurately determine the in-
volvement of a receptor. Indeed, mannan inhibited the
interaction of DCs with ManLAM to a similar extent as
DC-SIGN–specific antibodies, whereas MR-specific anti-
bodies did not block ManLAM binding. Moreover, the
MR-ligand mannose-BSA did not inhibit the interaction
of DC with M. bovis BCG (Fig. 3 c), demonstrating that
the mannose-specific C-type lectin domains of MR may
not be involved in M. bovis BCG infection of DCs. These
results demonstrate that DC-SIGN is an important C-type
lectin on DCs that interacts with the glycolipid ManLAM.
Moreover, captured ManLAM is rapidly internalized by
DCs upon DC-SIGN binding and targeted to CD107a/
LAMP-1  lysosomes (Fig. 4). DC-SIGN, in contrast to
MR, CD11b, and CD11c, was down-regulated after
ManLAM binding, which supports a role of DC-SIGN in
ManLAM internalization (Fig. 4). Uptake of M. tuberculosis
LAM by DCs results in presentation by CD1b to specific
T cells (4) and our results suggest that DC-SIGN may be
responsible for the delivery of ManLAM to late endo-
somes/lysosomes for presentation by CD1b. This is sup-
ported by the recent findings that DC-SIGN also func-
tions as an antigen receptor that targets internalized
antigen to late endosomes/lysosomes for presentation to T
cells (15). In contrast to our data, Prigozy et al. (4) sug-
gested a role for MR in the uptake of LAM, as the uptake
of LAM by immature DCs was inhibited by mannan and
LAM presentation was inhibited by polyclonal antibodies
against MR. The earlier observed block of LAM presenta-
tion (4) could be due to other domains in MR than the
C-type lectin domains, as we used monoclonal antibodies
that block the C-type lectin-mediated activity of MR.
This is further supported by our results that both mannan
and anti–DC-SIGN antibodies do not completely inhibit
the ManLAM interaction mediated by DCs (Fig. 3). Fu-
ture experiments comparing the DC-SIGN and MR func-
tion should reveal whether both are involved in CD1b
presentation of ManLAM.
Rapid internalization of ManLAM by DC-SIGN sug-
gests that DC-SIGN may also be involved in mycobacterial
uptake by DCs, as was shown for HIV-1 (10). Indeed,
blocking antibodies against DC-SIGN inhibit the internal-
ization of viable M. bovis BCG by immature DCs (Fig. 3).
Moreover, the erythroleukemic cell line K562 is unable to
internalize M. bovis BCG, whereas the K562 transfectant
expressing DC-SIGN internalizes viable M. bovis BCG.
Thus, DC-SIGN mediates both capture and internalization
of mycobacteria such as M. bovis BCG, which is supported
by the colocalization of DC-SIGN staining and FITC-con-
jugated mycobacteria (Fig. 4). Moreover, internalized
FITC-conjugated mycobacteria were targeted to the lyso-
somes, as they colocalized with LAMP-1 staining (Fig. 4).
Recently, it was shown that murine DCs can act as a reser-
voir in vivo for mycobacteria (33) and we cannot exclude
that bacilli escaped the lysosomal pathway to productively
infect human DCs.
LAM glycolipids are present in the mycobacterial cell
wall but are also secreted from phagosomes following mac-
rophage ingestion of M. tuberculosis (21, 23, 24). The pres-
ence of anti-LAM antibodies in sera of tuberculosis pa-
tients suggests that LAM is released in vivo (34). Thus,
mycobacteria within macrophages can affect bystander im-
mune cells and modulate the immune response mediated
by DCs. We demonstrate here that secreted ManLAM tar-
gets DC-SIGN on DCs to suppress DC functions (Figs.
5–7). Triggering of TLR on DCs induces the release of
cytokines and the up-regulation of accessory molecules for
efficient stimulation of T lymphocytes (35, 36) and DC
maturation by LPS is mediated through TLR4, which
generates intracellular signaling most notably via the tran-
scription factor NF- B (37). Mycobacteria such as M. bovis
BCG induce DC maturation (29; Fig. 7) and M. bovis
BCG can mediate the observed maturation through TR2
and TLR4 signaling (29). Strikingly, both M. bovis BCG-
and LPS-induced maturation of DCs was specifically
blocked by ManLAM but not by AraLAM (Figs. 6 and 7).
This inhibition by ManLAM is mediated through DC-
SIGN, as antibodies against DC-SIGN abrogated this ef-
fect and restored strong DC maturation by both M. bovis
BCG and LPS. These results suggest that DC-SIGN, upon
binding ManLAM, delivers a signal that interferes with the
M. bovis BCG-induced signals presumably generated by
TLR4. Our results demonstrate for the first time that
pathogen-binding to DC-SIGN may mediate intracellular
signaling. Ligation of DC-SIGN with antibodies alone is
not sufficient, as antibodies against DC-SIGN that trigger
internalization similarly to ManLAM (15; Fig. 4 b) did not
prevent DC activation (Figs. 6 and 7) nor induce IL-10
production (Fig. 5). The ManLAM-induced production of
IL-10 could contribute to the virulence of mycobacteria,
as IL-10 impairs the ability of DCs to generate Th1 re-
sponses by blocking up-regulation of costimulatory mole-
cules and IL-12 production (25). Moreover, M. bovisT
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BCG-infected DCs produced high levels of IL-10 (Fig. 5
b), demonstrating that mycobacteria induce IL-10 through
both direct infection and by influencing bystander DCs by
ManLAM secretion. Recently, it was demonstrated that
ManLAM inhibits the IL-12 production by LPS-matured
DCs (7). The authors suggested that MR is involved in
ManLAM binding, as a similar IL-12 down-regulation was
observed with anti-MR antibodies alone (7). Cross-linking
of MR may induce signals that block the LPS-induced IL-
12 up-regulation, and although we were unable to block
the interaction of ManLAM to DCs with the same anti-
MR monoclonal antibody (Fig. 3 b), it is possible that
other domains of MR are involved in ManLAM binding.
The authors hypothesized that pathogen receptors could
interfere with TLR signaling upon pathogen recognition,
modulating the cellular immune responses against patho-
gens (7). Our data further support this hypothesis, and this
may be a general principle by which pathogens suppress
the immune response (38).
Murine DCs are infected by mycobacteria both in vitro
and in vivo (33, 39) and the infected DCs rapidly lost their
antigen presentation ability upon infection by M. bovis
BCG in vivo (33). These observations support an impor-
tant role for DCs as hosts for mycobacteria. Moreover, our
observed inhibition of DC maturation and induction of IL-
10 by ManLAM–DC-SIGN demonstrates that in human
M. tuberculosis may target DC-SIGN to suppress cellular
immune responses since both immature DCs and IL-10–
treated DCs are not only less efficient at stimulating T cell
responses but can also induce a state of antigen-specific tol-
erance (40, 41). The results obtained with the mildly viru-
lent M. bovis BCG strain indicate that the mechanism of
immunosuppression may not directly contribute to the vir-
ulence and persistence of M. tuberculosis strains. However,
differences between the interaction of DC-SIGN with vir-
ulent and avirulent mycobacteria strains may account for
differences in persistence and will have to be investigated in
more detail.
Our results suggest that DC-SIGN is important in the
pathogenesis of M. tuberculosis, as was also demonstrated for
HIV-1 (10). DC-SIGN may be a prime target for patho-
gens such as HIV-1 and M. tuberculosis to manipulate the
DC function. Therefore, DC-SIGN could be an important
target for clinical intervention in M. tuberculosis and HIV-1
infections. The hypothesis of distinct binding sites in DC-
SIGN for cellular ligands and pathogen structures could
provide the molecular basis for the design of strategies to
inhibit DC-SIGN/pathogen interactions without affecting
the immunological function of DC-SIGN.
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